Biodesix is a private, molecular diagnostics company focusing on the development and commercialization of genomic and proteomic blood tests for patients with cancer. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for emerging therapies.
Founded in 2005, and originally headquartered in Steamboat Springs, Colorado, Biodesix was among the first to offer a proteomic blood test for clinical use, the VeriStrat test, developed using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) technology. The company later introduced a genomic test, GeneStrat, in 2016. The clinical
utility of the VeriStrat test gradually gained support through further studies examining the role of pretreatment serum proteomic testing.
In 2017, the company signed its first international collaboration agreement, with Bioyong Technology Company, Ltd, of Beijing, China, a developer and distributor of MALDI instruments for clinical use. Bioyong is currently developing a version of the VeriStrat test for use in Greater China. The company also entered into international sales and marketing agreements in Israel and India in 2017.
< Prev   Next >